SCHEMBL4861312

SCHEMBL4861312

CCOC(=O)COc1ccc(N(C)C(=O)OC(C)(C)C)cc1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 4/20 0.52
VDR P11473 1/20 0.41
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 2/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 2/20 0.40
MEN1 O00255 1/20 0.40
CASP1 P29466 1/20 0.40
KMT2A Q03164 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TSHR P16473 1/20 0.39
AR P10275 1/20 0.39
POLB P06746 2/20 0.39
ESR2 Q92731 1/20 0.39
CTDSP1 Q9GZU7 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
LMNA P02545 2/20 0.39
HDAC6 Q9UBN7 1/20 0.38
MAPK1 P28482 1/20 0.38
CASP3 P42574 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1549433 0.89 POLB (0.42) ESR1VDRALDH1A1KDM4EMEN1
SCHEMBL4860648 0.88 ALDH1A1 (0.46) ESR1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL4861398 0.88 ESR1 (0.42) ESR1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL4860564 0.88 ALDH1A1 (0.53) ESR1ALDH1A1KMT2ATSHRPOLB
SCHEMBL4859940 0.86 ESR1 (0.41) ESR1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL1549489 0.82 ESR1 (0.38) ESR1ALDH1A1MEN1KMT2ATSHR
SCHEMBL4853470 0.79 LMNA (0.38) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL4856543 0.79 ALDH1A1 (0.38) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL4852890 0.77 APP (0.44) ALDH1A1MEN1KMT2APOLBLMNA
SCHEMBL4416487 0.77 CASP3 (0.46) ALDH1A1KDM4EHPGDNPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7345067-B2 Aniline derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2008-03-18 US disclosed
EP-1636198-A1 ANILINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-03-22 EP disclosed
WO-2004111020-A1 ANILINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-12-23 WO disclosed
US-20040248951-A1 Aniline derivatives, their manufacture and use as pharmaceuticals F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248951-A1 Aniline derivatives, their manufacture and use as pharmaceuticals PPARA, PPARD, PPARG ESR1 1044/4885VDR 500/4885ALDH1A1 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.